Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
BUSINESS Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
-
BUSINESS Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
-
BUSINESS Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
-
REGULATORY MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
-
REGULATORY Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
-
REGULATORY Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
-
BUSINESS Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
-
BUSINESS Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
-
REGULATORY Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
-
BUSINESS Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
-
REGULATORY JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
-
REGULATORY Chuikyo OKs Drug Price Survey Plan for FY2027 Off-Year Revision
July 9, 2026
-
BUSINESS Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
-
BUSINESS Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
-
BUSINESS AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
-
REGULATORY LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
-
REGULATORY LDP Lawmakers Renew Calls to Reflect Inflation in Drug Prices
July 8, 2026
-
BUSINESS JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
-
REGULATORY LDP’s New Diabetes Caucus to Push Patients’ Social Participation
July 8, 2026
-
BUSINESS Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…